coagulation factor II, thrombin ; Homo sapiens

35 Article(s)
Pub. Year
#Total Relationships
1 32888192 Continuous intravenous infusion of enoxaparin controls thrombin formation more than standard subcutaneous administration in critically ill patients. A sub-study of the ENOKSI thromboprophylaxis RCT. 2021 Jan 1
2 31986476 Supplementation with antithrombin III ex vivo optimizes enoxaparin responses in critically injured patients. 2020 Mar 1
3 30713119 Anticoagulant activity of enoxaparin and unfractionated heparin for venous thromboembolism prophylaxis in obese patients undergoing sleeve gastrectomy. 2019 Mar 1
4 27609342 The Antithrombotic Potential of Tinzaparin and Enoxaparin Upon Thrombin Generation Triggered In Vitro by Human Ovarian Cancer Cells IGROV1. 2017 Mar 2
5 26927051 New Approaches to the Role of Thrombin in Acute Coronary Syndromes: Quo Vadis Bivalirudin, a Direct Thrombin Inhibitor? 2016 Feb 27 1
6 25396759 Results of rotational thromboelastometry, coagulation activation markers and thrombin generation assays in orthopedic patients during thromboprophylaxis with rivaroxaban and enoxaparin: a prospective cohort study. 2015 Mar 1
7 26489727 Cancer cells BXPC3 and MCF7 differentially reverse the inhibition of thrombin generation by apixaban, fondaparinux and enoxaparin. 2015 Dec 1
8 25406658 Changes in thrombin generation and D-dimer concentrations in women injecting enoxaparin during pregnancy and the puerperium. 2014 Nov 19 3
9 24094602 Lobectomy and postoperative thromboprophylaxis with enoxaparin improve blood hypercoagulability in patients with localized primary lung adenocarcinoma. 2013 Nov 3
10 21083516 Effects of enoxaparin preparations on thrombin generation and their correlation with their anti-FXa activity. 2011 Jan 1
11 21526168 Evaluation of the efficacy and safety of rivaroxaban using a computer model for blood coagulation. 2011 Apr 22 1
12 19517216 Efficacy of enoxaparin, certoparin and dalteparin in preventing cardiac catheter thrombosis: an in vitro approach. 2010 Apr 1
13 20505748 The mechanism of melanoma-associated thrombin activity and von Willebrand factor release from endothelial cells. 2010 Sep 2
14 21175312 Apixaban versus enoxaparin for thromboprophylaxis after hip replacement. 2010 Dec 23 1
15 18234290 Different effects of enoxaparin and unfractionated heparin on some thrombogenesis markers during hemodialysis: a cross-over study. 2009 Feb 1
16 19124079 Is thrombin generation the new rapid, reliable and relevant pharmacological tool for the development of anticoagulant drugs? 2009 Mar 1
17 17461929 Effect of the anti-factor Xa and anti-factor IIa activities of low-molecular-weight heparins upon the phases of thrombin generation. 2007 May 1
18 16420568 Thrombin generation time is a novel parameter for monitoring enoxaparin therapy in patients with end-stage renal disease. 2006 Feb 2
19 17670627 Initial experience of enoxaparine as anticoagulant during mechanical circulatory support in children. 2006 Aug 1
20 15091002 Comparison of the effect of fondaparinux and enoxaparin on thrombin generation during in-vitro clotting of whole blood and platelet-rich plasma. 2004 Mar 2
21 11454528 Effects of unfractionated and low molecular weight heparins on plasma levels of hemostatic factors in patients with acute coronary syndromes. 2001 Jul 3
22 11668418 Cellular effects of factor Xa on vascular smooth muscle cells--inhibition by heparins? 2001 Oct 1
23 11686357 Comparison of enoxaparin and unfractionated heparin on thrombin generation in acute coronary syndromes without ST-segment elevation. 2001 Oct 1
24 11755953 The lack of effect of a prophylactic dose of enoxaparin on thrombin generation in patients subjected to nephrectomy because of kidney cancer. 2001 Dec 15 1
25 10691099 Pharmacologic modulation of thrombin generation associated with human clots by human purified antithrombin alone or in the presence of low molecular weight heparin or unfractionated heparin. 2000 Jan 1
26 10728020 Enoxaparin, a low molecular weight heparin, inhibits platelet-dependent prothrombinase assembly and activity by factor-Xa neutralization. 2000 Apr 1
27 10947916 Inhibition of platelet-dependent prothrombinase activity and thrombin generation by glycoprotein IIb/IIIa receptor-directed antagonists: potential contributing mechanism of benefit in acute coronary syndromes. 2000 Aug 1
28 10500313 Thrombotic reactant markers in non-ST segment elevation acute coronary syndromes treated with either enoxaparin (low molecular weight heparin) or unfractionated heparin. 1999 Oct 2
29 10606110 Usefulness of intravenous enoxaparin for percutaneous coronary intervention in stable angina pectoris. 1999 Dec 15 1
30 10163420 Enoxaparin. A pharmacoeconomic appraisal of its use in thromboembolic prophylaxis after total hip arthroplasty. 1996 Aug 1
31 8703665 Comparison of biological activities of two low molecular weight heparins in 10 healthy volunteers. 1995 Dec 3
32 7900078 The effect of subcutaneous injection of unfractionated and low molecular weight heparin on thrombin generation in platelet rich plasma--a study in human volunteers. 1994 Nov 2
33 1325683 On the relationship between molecular mass and anticoagulant activity in a low molecular weight heparin (enoxaparin). 1992 May 4 1
34 1329919 The low molecular weight heparin Enoxaparin inhibits the consumption of factor VII and prothrombin activation in vivo associated with elective knee replacement surgery. 1992 Oct 2
35 2166377 [A simple test for the monitoring of plasma anti-XA activity of patients following subcutaneous administration of enoxaparin]. 1990 Jul 13 1